Avsnitt
-
Immunotherapeutic approaches, including CAR T-cells and bispecific antibodies, have become well-established in later lines of non-Hodgkin lymphoma (NHL) treatment. CAR...
The post The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies appeared first on VJHemOnc.
-
Saknas det avsnitt?
-
Smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS) are two well-known precursor conditions to multiple myeloma, and the...
The post Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification appeared first on VJHemOnc.
-
Clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS) are considered precursor diseases to hematologic malignancies,...
The post CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursors appeared first on VJHemOnc.
-
The introduction of CAR-T therapy has revolutionized the myeloma treatment landscape, offering a promising therapeutic approach for patients with relapsed/refractory...
The post The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT appeared first on VJHemOnc.
-
Although CAR-T cells have revolutionized the treatment of hematological malignancies, there are several important factors that must be addressed regarding...
The post Addressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapy appeared first on VJHemOnc.
-
The treatment landscape of acute lymphoblastic leukemia (ALL) has transformed with the introduction of novel immunotherapeutic agents, including CAR-T cells...
The post Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks appeared first on VJHemOnc.
-
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and rare hematological malignancy associated with poor prognosis. Several challenges remain...
The post Updates, challenges and novel agents being explored in BPDCN appeared first on VJHemOnc.
-
The treatment and management of patients with multiple myeloma is continually evolving, giving rise to novel prognostic tools and therapeutic...
The post Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets appeared first on VJHemOnc.
-
In recent years, the treatment and management of light chain (AL) amyloidosis has transformed with the introduction of novel agents....
The post ASH 2023 highlights: updates in the diagnosis and treatment of amyloidosis appeared first on VJHemOnc.
-
The treatment of the BCR-ABL1-negative myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), has transformed...
The post MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF appeared first on VJHemOnc.
- Visa fler